The United States has fired two heavy blows at the global pharmaceutical trade in the space of a week. First came an executive order from Washington to strengthen domestic supply of essential medicines and build a national reserve of active ingredients. Then followed a social media post from the US President threatening a 100% tariff on branded and patented drugs imported into America, unless the exporting company is already constructing manufacturing plants in the US. The IPA however clarified that the generics business is unlikely to be impacted.

“The executive order refers to patented / branded products supplied to US. It is not applicable to generics medicines,” said Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance (IPA).

US key market for Indian generics export

I

See Full Page